1. Basch E e t al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 2011; 7: 395-8.
2. Roila F et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 2010; 21 (Suppl 5): v232-43.
3. Grunberg SM et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 2005; 13: 80-84.
4. Gralla RJ et al. The 2004 Perugia Antiemetic Consensus Guideline process: Methods, procedures, and participants. Support Care Cancer 2005; 13: 77-79.
5. Hesketh PJ et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-9.
6. Koeller JM et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002; 10: 519-22.
7. Kris MG et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: Improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 1985; 69: 1257-62.
8. Roila F et al. Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002; 10: 88-95.
9. Roila F et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-8.
10. Kris MG et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24: 2932-47.
11. Roila F et al. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-8.
12. Jordan K et al. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007; 61: 162-75.
13. Rojas C et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010; 626: 193-9.
14. Saito M et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-24.
15. Eisenberg P et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-82.
16. Gralla R et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7.
17. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-94.
18. Hesketh PJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-9.
19. Loos WJ et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007; 59: 407-12.
20. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010; 21: 2316-23.
21. Rapoport BL et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer 2010; 18: 423-31.
22. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann Oncol 2007; 18: 233-40.
23. Passik SD et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: A Hoosier Oncology Group study. Cancer Invest 2004; 22: 383-8.
24. Navari RM et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study. Support Care Cancer 2007; 15: 1285-91.
25. Gralla R J et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17: 2971-94.
26. Jordan K et al. Antiemetische Prophylaxe und Therapie gemäß den MASCC und ASCO Guidelines. In: Deutsche Krebsgesellschaft e.V. (Hrsg). Kurzgefasste interdisziplinäre Leitlinien 2008. Zuckschwerdt, Germering bei München, 2008, S. 348-54.
27. Schmoll HJ et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17: 1000-6.
28. Tanioka M et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013; 109: 859-65.
29. Aapro MS et al. Anticipatory nausea and vomiting. Support Care Cancer 2005; 13: 117-21.
30. Morrow GR et al. Progress in reducing anticipatory nausea and vomiting: A study of community practice. Support Care Cancer 1998; 6: 46-50.
31. Aapro MS. How do we manage patients with refractory or breakthrough emesis? Support Care Cancer 2002; 10: 106-9.
32. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting – two new agents. J Support Oncol 2003; 1: 89-103.
33. Navari RM et al. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013; 21: 1655-63.
34. Herrstedt J. Nausea and emesis: Still an unsolved problem in cancer patients? Support Care Cancer 2002; 10: 85-7.